Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2016

How to report toxicity associated with targeted therapies?

Cabarrou B et al., Ann Oncol. 2016 Aug;27(8):1633-8.

2016

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

Blanchard P et al., Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92.

2016

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

Carrie C et al., Lancet Oncol. 2016 Jun;17(6):747-56.

2016

GENESIS: A French national resource to study the missing heritability of breast cancer.

Sinilnikova OM et al., BMC Cancer (2016) 16:13

2016

Mutation screening of MIR146A/B and BRCA1/2 3'UTRs in the GENESIS study

Garcia AI et al., Eur J Hum Genet. 2016 Aug;24(9):1324-9.

2016

Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

Danesi R et al., Ann Oncol. 2016 Sep 29.

2016

Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.

Fu Y et al., Cancer Res. 2016 Oct 15;76(20):5954-5961.

2015

"Maybe they have found something new" participants' views on returning cohort psychosocial survey results.

Bureau E et al, Health Expect. 2015 Dec;18(6):2425-36. doi: 10.1111/hex.12211. Epub 2014 May 30

2016

Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.

Garcia AI et al., Eur J Hum Genet. 2016 Jan 20. doi: 10.1038/ejhg.2015.284

2015

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Bougeard G et al., J Clin Oncol. 2015 Jul 20;33(21):2345-52. doi: 10.1200/JCO.2014.59.5728. Epub 2015 May 26